Treatment of neuropathic pain remains inadequate despite the elucidation of multiple pathophysiological mechanisms and the development of promising therapeutic compounds. The lack of success in translating knowledge into clinical practice has discouraged pharmaceutical companies from investing in pain medicine; however, new patient stratification approaches could help bridge the translation gap and develop individualized therapeutic approaches. As we highlight in this article, subgrouping of patients according to sensory profiles and other baseline characteristics could aid the prediction of treatment success. Furthermore, novel outcome measures have been developed for patients with neuropathic pain. The extent to which sensory profiles and outcome measures can be employed in routine clinical practice and clinical trials and across distinct neuropathic pain aetiologies is yet to be determined. Improvements in animal models, drawing on our knowledge of human pain, and robust public–private partnerships will be needed to pave the way to innovative and effective pain medicine in the future.
This is a preview of subscription content, access via your institution
Subscribe to Nature+
Get immediate online access to Nature and 55 other Nature journal
Subscribe to Journal
Get full journal access for 1 year
only $6.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Colloca, L. et al. Neuropathic pain. Nat. Rev. Dis. Prim. 3, 17002 (2017).
Alsaloum, M., Higerd, G. P., Effraim, P. R. & Waxman, S. G. Status of peripheral sodium channel blockers for non-addictive pain treatment. Nat. Rev. Neurol. 16, 689–705 (2020).
Finnerup, N. B. et al. Neuropathic pain clinical trials: factors associated with decreases in estimated drug efficacy. Pain 159, 2339–2346 (2018).
Mbowe, O. B., Gewandter, J. S., Turk, D. C., Dworkin, R. H. & McDermott, M. P. Are there really only 2 kinds of people in the world? Evaluating the distribution of change from baseline in pain clinical trials. Pain 161, 195–201 (2020).
Attal, N., Bouhassira, D. & Baron, R. Diagnosis and assessment of neuropathic pain through questionnaires. Lancet Neurol. 17, 456–466 (2018).
Pascal, M. M. V. et al. DOLORisk: study protocol for a multi-centre observational study to understand the risk factors and determinants of neuropathic pain. Wellcome Open Res. 3, 63 (2018).
Corder, G. et al. An amygdalar neural ensemble that encodes the unpleasantness of pain. Science 363, 276–281 (2019).
Daou, I. et al. Remote optogenetic activation and sensitization of pain pathways in freely moving mice. J. Neurosci. 33, 18631–18640 (2013).
Soliman, N., Rice, A. S. C. & Vollert, J. A practical guide to preclinical systematic review and meta-analysis. Pain 161, 1949–1954 (2020).
Rice, A. S. C. et al. Transparency in the reporting of in vivo pre-clinical pain research: the relevance and implications of the ARRIVE (animal research: reporting in vivo experiments) guidelines. Scand. J. Pain 4, 58–62 (2013).
Knopp, K. L. et al. Experimental design and reporting standards for improving the internal validity of pre-clinical studies in the field of pain: consensus of the IMI-Europain consortium. Scand. J. Pain 7, 58–70 (2015).
Decosterd, I. & Woolf, C. J. Spared nerve injury: an animal model of persistent peripheral neuropathic pain. Pain 87, 149–158 (2000).
Dickenson, A. H. & Patel, R. Translational issues in precision medicine in neuropathic pain. Can. J. Pain 4, 30–38 (2020).
Field, M. J. et al. Identification of the α2-δ-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin. Proc. Natl Acad. Sci. USA 103, 17537–17542 (2006).
Patel, R. & Dickenson, A. H. Neuronal hyperexcitability in the ventral posterior thalamus of neuropathic rats: modality selective effects of pregabalin. J. Neurophysiol. 116, 159–170 (2016).
Demant, D. T. et al. The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double-blind, placebo-controlled phenotype-stratified study. Pain 155, 2263–2273 (2014).
Patel, R., Kucharczyk, M., Montagut-Bordas, C., Lockwood, S. & Dickenson, A. H. Neuropathy following spinal nerve injury shares features with the irritable nociceptor phenotype: a back-translational study of oxcarbazepine. Eur. J. Pain 23, 183–197 (2019).
McDonnell, A. et al. Efficacy of the Nav1.7 blocker PF-05089771 in a randomised, placebo-controlled, double-blind clinical study in subjects with painful diabetic peripheral neuropathy. Pain 159, 1465–1476 (2018).
Cao, L. et al. Pharmacological reversal of a pain phenotype in iPSC-derived sensory neurons and patients with inherited erythromelalgia. Sci. Transl. Med. 8, 335ra56 (2016).
Goodwin, G., McMurray, S., Stevens, E. B., Denk, F. & McMahon, S. B. Examination of the contribution of Nav1.7 to axonal propagation in nociceptors. Pain 163, e869–e881 (2022).
Kraus, R. L. et al. Nav1.7 target modulation and efficacy can be measured in nonhuman primate assays. Sci. Transl. Med. 13, eaay1050 (2021).
Gewandter, J. S. et al. Predicting treatment response with sensory phenotyping in post-traumatic neuropathic pain. Pain. Med. 23, 1726–1732 (2022).
Fisher, A. S., Lanigan, M. T., Upton, N. & Lione, L. A. Preclinical neuropathic pain assessment; the importance of translatability and bidirectional research. Front. Pharmacol. 11, 614990 (2020).
Hunt, J., Knazovicky, D., Lascelles, B. D. X. & Murrell, J. Quantitative sensory testing in dogs with painful disease: a window to pain mechanisms? Vet. J. 243, 33–41 (2019).
Edvinsson, L. CGRP and migraine: from bench to bedside. Rev. Neurol. 177, 785–790 (2021).
Wise, B. L., Seidel, M. F. & Lane, N. E. The evolution of nerve growth factor inhibition in clinical medicine. Nat. Rev. Rheumatol. 17, 34–46 (2021).
Claussnitzer, M. et al. A brief history of human disease genetics. Nature 577, 179–189 (2020).
Calvo, M. et al. The genetics of neuropathic pain from model organisms to clinical application. Neuron 104, 637–653 (2019).
Zorina-Lichtenwalter, K., Parisien, M. & Diatchenko, L. Genetic studies of human neuropathic pain conditions: a review. Pain 159, 583–594 (2018).
Sun, B. B. et al. Genetic associations of protein-coding variants in human disease. Nature 603, 95–102 (2022).
Burand, A. J. & Stucky, C. L. Fabry disease pain: patient and preclinical parallels. Pain 162, 1305–1321 (2021).
Asiri, M. M. H., Engelsman, S., Eijkelkamp, N. & Höppener, J. W. M. Amyloid proteins and peripheral neuropathy. Cells 9, E1553 (2020).
Adams, D., Koike, H., Slama, M. & Coelho, T. Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease. Nat. Rev. Neurol. 15, 387–404 (2019).
Houlden, H. et al. Clinical, pathological and genetic characterization of hereditary sensory and autonomic neuropathy type 1 (HSAN I). Brain 129, 411–425 (2006).
Kok, K. et al. Fabry disease: molecular basis, pathophysiology, diagnostics and potential therapeutic directions. Biomolecules 11, 271 (2021).
Sachau, J., Kersebaum, D., Baron, R. & Dickenson, A. H. Unusual pain disorders–what can be learned from them? J. Pain Res. 13, 3539–3554 (2020).
Fridman, V. et al. Randomized trial of l-serine in patients with hereditary sensory and autonomic neuropathy type 1. Neurology 92, e359–e370 (2019).
Bennett, D. L., Clark, A. J., Huang, J., Waxman, S. G. & Dib-Hajj, S. D. The role of voltage-gated sodium channels in pain signaling. Physiol. Rev. 99, 1079–1151 (2019).
Shiers, S. I. et al. Convergence of peptidergic and non-peptidergic protein markers in the human dorsal root ganglion and spinal dorsal horn. J. Comp. Neurol. 529, 2771–2788 (2021).
Tavares-Ferreira, D. et al. Spatial transcriptomics of dorsal root ganglia identifies molecular signatures of human nociceptors. Sci. Transl. Med. 14, eabj8186 (2022).
Cox, J. J. et al. An SCN9A channelopathy causes congenital inability to experience pain. Nature 444, 894–898 (2006).
Yang, Y. et al. Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia. J. Med. Genet. 41, 171–174 (2004).
Dib-Hajj, S. D. et al. Gain-of-function mutation in Nav1.7 in familial erythromelalgia induces bursting of sensory neurons. Brain 128, 1847–1854 (2005).
Fertleman, C. R. et al. SCN9A mutations in paroxysmal extreme pain disorder: allelic variants underlie distinct channel defects and phenotypes. Neuron 52, 767–774 (2006).
Devigili, G. et al. Diagnostic criteria for small fibre neuropathy in clinical practice and research. Brain 142, 3728–3736 (2019).
Hoeijmakers, J. G., Faber, C. G., Lauria, G., Merkies, I. S. & Waxman, S. G. Small-fibre neuropathies – advances in diagnosis, pathophysiology and management. Nat. Rev. Neurol. 8, 369–379 (2012).
Faber, C. G. et al. Gain of function Naν1.7 mutations in idiopathic small fiber neuropathy. Ann. Neurol. 71, 26–39 (2012).
Huang, J. et al. Sodium channel NaV1.9 mutations associated with insensitivity to pain dampen neuronal excitability. J. Clin. Invest. 127, 2805–2814 (2017).
Leipold, E. et al. A de novo gain-of-function mutation in SCN11A causes loss of pain perception. Nat. Genet. 45, 1399–1404 (2013).
Kremeyer, B. et al. A gain-of-function mutation in TRPA1 causes familial episodic pain syndrome. Neuron 66, 671–680 (2010).
Blesneac, I. et al. Rare NaV1.7 variants associated with painful diabetic peripheral neuropathy. Pain 159, 469–480 (2018).
Li, Q. S. et al. SCN9A variants may be implicated in neuropathic pain associated with diabetic peripheral neuropathy and pain severity. Clin. J. Pain 31, 976–982 (2015).
Reimann, F. et al. Pain perception is altered by a nucleotide polymorphism in SCN9A. Proc. Natl Acad. Sci. USA 107, 5148–5153 (2010).
Alsaloum, M. et al. A gain-of-function sodium channel β2-subunit mutation in painful diabetic neuropathy. Mol. Pain. 15, 1744806919849802 (2019).
Alsaloum, M. et al. A novel gain-of-function sodium channel β2 subunit mutation in idiopathic small fiber neuropathy. J. Neurophysiol. 126, 827–839 (2021).
Binder, A. et al. Transient receptor potential channel polymorphisms are associated with the somatosensory function in neuropathic pain patients. PLoS ONE 6, e17387 (2011).
Veluchamy, A., Hébert, H. L., Meng, W., Palmer, C. N. A. & Smith, B. H. Systematic review and meta-analysis of genetic risk factors for neuropathic pain. Pain 159, 825–848 (2018).
Hearn, L., Derry, S. & Moore, R. A. Lacosamide for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst. Rev. https://doi.org/10.1002/14651858.CD009318.pub2 (2012).
de Greef, B. T. A. et al. Lacosamide in patients with Nav1.7 mutations-related small fibre neuropathy: a randomized controlled trial. Brain 142, 263–275 (2019).
Labau, J. I. R. et al. Differential effect of lacosamide on Nav1.7 variants from responsive and non-responsive patients with small fibre neuropathy. Brain 143, 771–782 (2020).
Yang, Y. et al. Structural modelling and mutant cycle analysis predict pharmacoresponsiveness of a Na(V)1.7 mutant channel. Nat. Commun. 3, 1186 (2012).
Geha, P. et al. Pharmacotherapy for pain in a family with inherited erythromelalgia guided by genomic analysis and functional profiling. JAMA Neurol. 73, 659–667 (2016).
Han, C. et al. The novel activity of carbamazepine as an activation modulator extends from NaV1.7 mutations to the NaV1.8-S242T mutant channel from a patient with painful diabetic neuropathy. Mol. Pharmacol. 94, 1256–1269 (2018).
Costigan, M., Scholz, J. & Woolf, C. J. Neuropathic pain: a maladaptive response of the nervous system to damage. Annu. Rev. Neurosci. 32, 1–32 (2009).
Gold, M. S. & Gebhart, G. F. Nociceptor sensitization in pain pathogenesis. Nat. Med. 16, 1248–1257 (2010).
Finnerup, N. B. et al. Neuropathic pain: an updated grading system for research and clinical practice. Pain 157, 1599–1606 (2016).
Wainger, B. J. et al. Effect of ezogabine on cortical and spinal motor neuron excitability in amyotrophic lateral sclerosis: a randomized clinical trial. JAMA Neurol. 78, 186–196 (2021).
Misawa, S. et al. Neuropathic pain is associated with increased nodal persistent Na(+) currents in human diabetic neuropathy. J. Peripher. Nerv. Syst. 14, 279–284 (2009).
Serra, J. et al. Hyperexcitable C nociceptors in fibromyalgia. Ann. Neurol. 75, 196–208 (2014).
Serra, J. et al. Effects of a T-type calcium channel blocker, ABT-639, on spontaneous activity in C-nociceptors in patients with painful diabetic neuropathy: a randomized controlled trial. Pain 156, 2175–2183 (2015).
McDermott, L. A. et al. Defining the functional role of NaV1.7 in human nociception. Neuron 101, 905–919.e8 (2019).
Chambers, S. M. et al. Combined small-molecule inhibition accelerates developmental timing and converts human pluripotent stem cells into nociceptors. Nat. Biotechnol. 30, 715–720 (2012).
Mis, M. A. et al. Resilience to pain: a peripheral component identified using induced pluripotent stem cells and dynamic clamp. J. Neurosci. 39, 382–392 (2019).
Yuan, J.-H. et al. KCNQ variants and pain modulation: a missense variant in Kv7.3 contributes to pain resilience. Brain Commun. 3, fcab212 (2021).
Meents, J. E. et al. The role of Nav1.7 in human nociceptors: insights from human induced pluripotent stem cell-derived sensory neurons of erythromelalgia patients. Pain 160, 1327–1341 (2019).
Pettingill, P. et al. A causal role for TRESK loss of function in migraine mechanisms. Brain 142, 3852–3867 (2019).
Middleton, S. J. et al. Studying human nociceptors: from fundamentals to clinic. Brain 144, 1312–1335 (2021).
MacDonald, D. I. et al. A central mechanism of analgesia in mice and humans lacking the sodium channel NaV1.7. Neuron 109, 1497–1512.e6 (2021).
Namer, B. et al. Pain relief in a neuropathy patient by lacosamide: proof of principle of clinical translation from patient-specific iPS cell-derived nociceptors. EBioMedicine 39, 401–408 (2019).
Strimbu, K. & Tavel, J. A. What are biomarkers? Curr. Opin. Hiv. AIDS 5, 463–466 (2010).
Preische, O. et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease. Nat. Med. 25, 277–283 (2019).
Varhaug, K. N., Torkildsen, Ø., Myhr, K.-M. & Vedeler, C. A. Neurofilament light chain as a biomarker in multiple sclerosis. Front. Neurol. 10, 338 (2019).
Sandelius, Å. et al. Plasma neurofilament light chain concentration in the inherited peripheral neuropathies. Neurology 90, e518–e524 (2018).
Kim, S.-H. et al. Serum neurofilament light chain levels as a biomarker of neuroaxonal injury and severity of oxaliplatin-induced peripheral neuropathy. Sci. Rep. 10, 7995 (2020).
Morgenstern, J. et al. Neuron-specific biomarkers predict hypo- and hyperalgesia in individuals with diabetic peripheral neuropathy. Diabetologia 64, 2843–2855 (2021).
Celikbilek, A. et al. Elevated neurofilament light chain (NFL) mRNA levels in prediabetic peripheral neuropathy. Mol. Biol. Rep. 41, 4017–4022 (2014).
Iyengar, S., Johnson, K. W., Ossipov, M. H. & Aurora, S. K. CGRP and the trigeminal system in migraine. Headache 59, 659–681 (2019).
Sommer, C., Leinders, M. & Üçeyler, N. Inflammation in the pathophysiology of neuropathic pain. Pain 159, 595–602 (2018).
Sandy-Hindmarch, O. et al. Systemic inflammatory markers in neuropathic pain, nerve injury, and recovery. Pain 163, 526–537 (2022).
Ajit, S. K. Circulating microRNAs as biomarkers, therapeutic targets, and signaling molecules. Sensors 12, 3359–3369 (2012).
Orlova, I. A. et al. MicroRNA modulation in complex regional pain syndrome. J. Transl. Med. 9, 195 (2011).
McDonald, M. K. et al. Functional significance of macrophage-derived exosomes in inflammation and pain. Pain 155, 1527–1539 (2014).
Kalpachidou, T., Kummer, K. K. & Kress, M. Non-coding RNAs in neuropathic pain. Neuronal Signal. 4, NS20190099 (2020).
Yu, W., Zhao, G.-Q., Cao, R.-J., Zhu, Z.-H. & Li, K. LncRNA NONRATT021972 was associated with neuropathic pain scoring in patients with type 2 diabetes. Behav. Neurol. 2017, 2941297 (2017).
Luo, L. et al. Microarray analysis of long noncoding RNAs in female diabetic peripheral neuropathy patients. Cell Physiol. Biochem. 46, 1209–1217 (2018).
Shenoda, B. B. et al. miR-34a-mediated regulation of XIST in female cells under inflammation. J. Pain Res. 11, 935–945 (2018).
Wang, L., Luo, T., Bao, Z., Li, Y. & Bu, W. Intrathecal circHIPK3 shRNA alleviates neuropathic pain in diabetic rats. Biochem. Biophys. Res. Commun. 505, 644–650 (2018).
Tracey, I., Woolf, C. J. & Andrews, N. A. Composite pain biomarker signatures for objective assessment and effective treatment. Neuron 101, 783–800 (2019).
Xu, A. et al. Convergent neural representations of experimentally-induced acute pain in healthy volunteers: a large-scale fMRI meta-analysis. Neurosci. Biobehav. Rev. 112, 300–323 (2020).
Mackey, S., Greely, H. T. & Martucci, K. T. Neuroimaging-based pain biomarkers: definitions, clinical and research applications, and evaluation frameworks to achieve personalized pain medicine. Pain. Rep. 4, e762 (2019).
Wanigasekera, V. et al. Disambiguating pharmacological mechanisms from placebo in neuropathic pain using functional neuroimaging. Br. J. Anaesth. 120, 299–307 (2018).
Wanigasekera, V., Mezue, M., Andersson, J., Kong, Y. & Tracey, I. Disambiguating pharmacodynamic efficacy from behavior with neuroimaging: implications for analgesic drug development. Anesthesiology 124, 159–168 (2016).
Soni, A. et al. Central sensitization in knee osteoarthritis: relating presurgical brainstem neuroimaging and PainDETECT-based patient stratification to arthroplasty outcome. Arthritis Rheumatol. 71, 550–560 (2019).
Pud, D. et al. Can personality traits and gender predict the response to morphine? An experimental cold pain study. Eur. J. Pain 10, 103–112 (2006).
Wasan, A. D. et al. Psychiatric comorbidity is associated prospectively with diminished opioid analgesia and increased opioid misuse in patients with chronic low back pain. Anesthesiology 123, 861–872 (2015).
Jamison, R. N. et al. Relationship of negative affect and outcome of an opioid therapy trial among low back pain patients. Pain. Pract. 13, 173–181 (2013).
Marchettini, P. et al. Are there different predictors of analgesic response between antidepressants and anticonvulsants in painful diabetic neuropathy? Eur. J. Pain 20, 472–482 (2016).
Smith, E. M. L. et al. Predictors of duloxetine response in patients with oxaliplatin-induced painful chemotherapy-induced peripheral neuropathy (CIPN): a secondary analysis of randomised controlled trial–CALGB/alliance 170601. Eur. J. Cancer Care https://doi.org/10.1111/ecc.12421 (2015).
Kern, A., Kramm, C., Witt, C. M. & Barth, J. The influence of personality traits on the placebo/nocebo response: a systematic review. J. Psychosom. Res. 128, 109866 (2020).
Raputova, J. et al. Sensory phenotype and risk factors for painful diabetic neuropathy: a cross-sectional observational study. Pain 158, 2340–2353 (2017).
Miller, R. M. & Kaiser, R. S. Psychological characteristics of chronic pain: a review of current evidence and assessment tools to enhance treatment. Curr. Pain. Headache Rep. 22, 22 (2018).
Pisanu, C. et al. Sex differences in the response to opioids for pain relief: a systematic review and meta-analysis. Pharmacol. Res. 148, 104447 (2019).
Hurley, R. W. & Adams, M. C. B. Sex, gender, and pain: an overview of a complex field. Anesth. Analg. 107, 309–317 (2008).
Boussageon, R. et al. How do they add up? The interaction between the placebo and treatment effect: a systematic review. Br. J. Clin. Pharmacol. 88, 3638–3656 (2022).
Vase, L., Riley, J. L. & Price, D. D. A comparison of placebo effects in clinical analgesic trials versus studies of placebo analgesia. Pain 99, 443–452 (2002).
Vase, L. & Wartolowska, K. Pain, placebo, and test of treatment efficacy: a narrative review. Br. J. Anaesth. 123, e254–e262 (2019).
Enck, P., Bingel, U., Schedlowski, M. & Rief, W. The placebo response in medicine: minimize, maximize or personalize? Nat. Rev. Drug Discov. 12, 191–204 (2013).
Baron, R., Förster, M. & Binder, A. Subgrouping of patients with neuropathic pain according to pain-related sensory abnormalities: a first step to a stratified treatment approach. Lancet Neurol. 11, 999–1005 (2012).
Rolke, R. et al. Quantitative sensory testing in the German Research Network on neuropathic pain (DFNS): standardized protocol and reference values. Pain 123, 231–243 (2006).
Baron, R. et al. Peripheral neuropathic pain: a mechanism-related organizing principle based on sensory profiles. Pain 158, 261–272 (2017).
Vollert, J. et al. Stratifying patients with peripheral neuropathic pain based on sensory profiles: algorithm and sample size recommendations. Pain 158, 1446–1455 (2017).
Jain, S. M. et al. Randomized, double-blind, placebo-controlled trial of ISC 17536, an oral inhibitor of transient receptor potential ankyrin 1, in patients with painful diabetic peripheral neuropathy: impact of preserved small nerve fiber function. Pain 163, e738–e747 (2022).
Attal, N. et al. Safety and efficacy of repeated injections of botulinum toxin A in peripheral neuropathic pain (BOTNEP): a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 15, 555–565 (2016).
European Medicines Agency. Guideline on the clinical development of medicinal products for the treatment of pain. Committee for Medicinal Products for Human Use. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-development-medicinal-products-intended-treatment-pain-first-version_en.pdf (2016).
Yarnitsky, D., Granot, M., Nahman-Averbuch, H., Khamaisi, M. & Granovsky, Y. Conditioned pain modulation predicts duloxetine efficacy in painful diabetic neuropathy. Pain 153, 1193–1198 (2012).
Kennedy, D. L., Kemp, H. I., Ridout, D., Yarnitsky, D. & Rice, A. S. C. Reliability of conditioned pain modulation: a systematic review. Pain 157, 2410–2419 (2016).
Bouhassira, D. et al. Development and validation of the neuropathic pain symptom inventory. Pain 108, 248–257 (2004).
Otto, J. C., Gierthmühlen, J., Kirchhofer, V., Borzikowsky, C. & Baron, R. Validation of the questionnaire for symptom assessment in pain disorders for back pain patients (Q-SAP). Eur. J. Pain 25, 513–528 (2021).
Tölle, T. R. et al. painPREDICT: first interim data from the development of a new patient-reported pain questionnaire to predict treatment response using sensory symptom profiles. Curr. Med. Res. Opin. 35, 1177–1185 (2019).
Bouhassira, D. et al. Stratification of patients based on the neuropathic pain symptom inventory: development and validation of a new algorithm. Pain 162, 1038–1046 (2021).
Vollert, J. et al. The need for previous knowledge does not render quantitative sensory testing a ‘failure’ but part of a larger picture of the relationship between nociception and pain. Pain 162, 1273–1274 (2021).
Reimer, M. et al. Sensory bedside testing: a simple stratification approach for sensory phenotyping. Pain. Rep. 5, e820 (2020).
Reimer, M., Sachau, J., Forstenpointner, J. & Baron, R. Bedside testing for precision pain medicine. Curr. Opin. Support. Palliat. Care 15, 116–124 (2021).
Sachau, J. et al. Test-retest reliability of a simple bedside-quantitative sensory testing battery for chronic neuropathic pain. J. Pain https://doi.org/10.1016/j.jpain.2019.11.013 (2019).
Otto, J. C. et al. A novel algorithm to identify predictors of treatment response: tapentadol monotherapy or tapentadol/pregabalin combination therapy in chronic low back pain? Front. Neurol. 10, 979 (2019).
Reimer, M. et al. Prediction of response to tapentadol in chronic low back pain. Eur. J. Pain 21, 322–333 (2017).
Wesolowska-Andersen, A. et al. Four groups of type 2 diabetes contribute to the etiological and clinical heterogeneity in newly diagnosed individuals: an IMI DIRECT study. Cell Rep. Med. 3, 100477 (2022).
Scholz, J. et al. The IASP classification of chronic pain for ICD-11: chronic neuropathic pain. Pain 160, 53–59 (2019).
Treede, R.-D. et al. A classification of chronic pain for ICD-11. Pain 156, 1003–1007 (2015).
Kosek, E. et al. Chronic nociplastic pain affecting the musculoskeletal system: clinical criteria and grading system. Pain 162, 2629–2634 (2021).
Turk, D. C. et al. Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. Pain 106, 337–345 (2003).
Patel, K. V. et al. Clinical outcome assessment in clinical trials of chronic pain treatments. Pain. Rep. 6, e784 (2021).
Sachau, J. et al. Patient reported outcome measures in chronic neuropathic pain clinical trials–a systematic literature review. J. Pain https://doi.org/10.1016/j.jpain.2022.09.003 (2022).
Gewandter, J. S. et al. Composite outcomes for pain clinical trials: considerations for design and interpretation. Pain 162, 1899–1905 (2021).
Renthal, W. et al. Human cells and networks of pain: transforming pain target identification and therapeutic development. Neuron 109, 1426–1429 (2021).
R.B. has received R.B. has received research funding from EU Projects Europain (115007), DOLORisk (633491), IMI Paincare (777500), the German Federal Ministry of Education and Research (BMBF): Verbundprojekt: Frühdetektion von Schmerzchronifizierung (NoChro) (13GW0338C), German Research Network on Neuropathic Pain (01EM0903), Pfizer, Grünenthal, Mundi Pharma, Alnylam, Zambon, Bayer, Sanofi Aventis. He has been a speaker for Pfizer, Sanofi Aventis, Grünenthal, Mundipharma, Lilly, Desitin, Teva, Bayer, MSD, Seqirus, Novartis, TAD, Eva, Takeda, Ology, Ever, Amicus, Novo Nordisk, Chiesi, Stada, Hexal, Viatris. He has acted as a consultant for Pfizer, Sanofi Aventis, Grünenthal, Lilly, Novartis, Bristol-Myers Squibb, Biogenidec, AstraZeneca, Daiichi Sankyo, Glenmark, Seqirus, Teva, Genentech, Mundipharma, Galapagos, Kyowa Kirin, Vertex, Biotest, Celgene, Desitin, Regeneron, Theranexus, Abbott, Bayer, Akcea, Asahi Kasei, AbbVie, Air Liquide, Alnylam, Lateral, Hexal, Angelini, Janssen, SIMR, Confo, Merz, Neumentum, Hoffmann-La Roche, AlgoTherapeutix, Nanobiotix, AmacaThera. M.C. is a councillor at the International Society for the Study of Pain (IASP), a board member of the Neuropathic Pain Special Interest Group of IASP and a board member of the Neuropathic Pain Consortium (SIG of Peripheral Nerve Society). D.L.B. has acted as a consultant on behalf of Oxford Innovation for Amgen, Bristows, LatigoBio, GSK, Ionis, Lilly, Olipass, Orion, Regeneron and Theranexus over the past 2 years. He has received research funding from Lilly and AstraZeneca. He is an inventor for patent application ‘A method for the treatment or prevention of pain or excessive neuronal activity or epilepsy’ (application no. US16/337,428). He is a member of the Medical Reseach Council Neuroscience and Mental Health Board for which he receives reimbursement. He is an executive member of the Neuropathic Pain Special Interest Group of IASP. S.D.D.-H. has consulted with Ionis and Alnylam Pharmaceuticals over the past 2 years and is a board member of the Neuropathic Pain Special Interest Group of IASP. A.H.D. declares no competing interests.
Peer review information
Nature Reviews Neurology thanks L. Asan, who co-reviewed with U. Bingel; M. Schmelz; I. Gilron; and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT): http://www.immpact.org
Innovative Medicines Initiative (IMI)-PainCare Consortium: https://www.imi-paincare.eu
About this article
Cite this article
Baron, R., Dickenson, A.H., Calvo, M. et al. Maximizing treatment efficacy through patient stratification in neuropathic pain trials. Nat Rev Neurol (2022). https://doi.org/10.1038/s41582-022-00741-7